Drug Interactions between Grisactin 250 and Jevtana
This report displays the potential drug interactions for the following 2 drugs:
- Grisactin 250 (griseofulvin)
- Jevtana (cabazitaxel)
Interactions between your drugs
griseofulvin cabazitaxel
Applies to: Grisactin 250 (griseofulvin) and Jevtana (cabazitaxel)
GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme. However, no formal drug interaction studies have been conducted.
MANAGEMENT: Concomitant use of cabazitaxel with potent CYP450 3A4 inducers such as apalutamide, carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort should generally be avoided. The extent to which other, less potent CYP450 3A4 inducers may interact with cabazitaxel is unknown. Caution is advised if they are used with cabazitaxel.
References
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
Drug and food interactions
griseofulvin food
Applies to: Grisactin 250 (griseofulvin)
MONITOR: Isolated case reports have suggested that the ingestion of alcohol during griseofulvin therapy may rarely cause disulfiram-like reactions, flushing, tachycardia, or increased effects of alcohol. The mechanism is unknown.
MANAGEMENT: Patients should be advised of the possibility of increased adverse effects or a disulfiram-like reaction.
References
- "Product Information. Grifulvin V (griseofulvin)." Ortho McNeil Pharmaceutical
- "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation PROD (2002):
- Cerner Multum, Inc. "Australian Product Information." O 0
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.